The eValuation of Image Guidance of Stereotactic Body Radiotherapy Using Ultrasound: Assessment in Liver
NCT ID: NCT03592550
Last Updated: 2018-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
26 participants
OBSERVATIONAL
2018-09-30
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma
NCT01668134
Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant
NCT01194206
Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm
NCT01825824
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
NCT07305428
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
NCT05053555
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
RECRUITMENT: Volunteers will need to provide their National Health Service (UK) numbers and be registered on the hospital information system. Volunteers need to be aware that if they are patients at the Royal Marsden Hospital this may raise confidentiality issues. Volunteers will be made aware of this in the recruiting email and the Volunteer Information sheet.
USE OF HEALTHY VOLUNTEERS: This is an observational study, which tests the use of an ultrasound guidance system. The accuracy of the system will be evaluated by comparison of proprietary methods of liver position estimation against a manually derived ground truth derived from the images of the liver acquired in participants. It is not expected that there are any differences in the ultrasound guidance images of healthy volunteers and patients with liver cancer. Ultrasound is a non-invasive and non-ionizing imaging modality with no known side-effects or complications and therefore, safe to use in a volunteer study. Furthermore, this study requires that participants lie on a hard couch for up to 45 minutes and up to 4 times. This would be challenging for the vast majority of patients with liver cancer who are most likely to be frail due to their disease.
REVIEW OF HEALTHY VOLUNTEERS: The ultrasound guidance system provides 3D ultrasound images of the liver for providing positional information only. It is very unlikely that abnormalities will be detectable on 3D US guidance images. These images are not of diagnostic quality, being lower resolution than routine diagnostic 2D ultrasound images. Furthermore, diagnostic ultrasound of the liver often incorporates ultrasound contrast agent, which will not be used in this study. If a radiographer does observe any abnormality, this will be reported to a Consultant Radiologist and the images will be made available for review.
RISKS, BURDENS and BENEFITS: There is very little risk associated with ultrasound and the Automatic Breathing Control (ABC) device, both pieces of the equipment are CE-marked and we are not using outside of their respective intended purposes. The burden to the volunteer is (1) the time spent, (2) the uncomfortable nature of the couch (it has a hard flat surface) and (3) discomfort using the ABC device. The participant will made aware of (1), (2) and (3) by providing details in the volunteer information sheet. Participants who are uncomfortable using the ABC can opt out and still participate in the study. Participants will be able to get up from the couch and walk around to relive any discomfort at any point during the imaging sessions.
There are no benefits for the participants. It is expected that this study will be of benefit to future patients with liver cancer. To ensure there is no perceived benefit of the acquisition of ultrasound images it is stated clearly in the volunteer information sheet that images are not of diagnostic quality and that persons obtaining the images are trained in therapy guidance and not diagnostics, and that images will only be reviewed by a radiologist in the unlikely event that an abnormality is observed.
CONFLICTS OF INTEREST: There are no conflicts of interest. No study investigator will benefit financially from the outcome of this study. The manufacturer of the Clarity ultrasound system will be informed of the results and all results will be published in a peer-reviewed scientific journal.
ACCESS to DATA: The investigators wish to make anonymised image data available to other researchers on request for the purpose of medical research. This is intended to maximise the value of the data and may provide greater benefit to patients. Volunteers will be asked to consent to their anonymised data being made available to other researchers.
AIMS: This study aims to develop and evaluate the use of 3 ultrasound (3DUS) to estimate the liver position for radiotherapy guidance. This is an exploratory study, where Clarity US of the abdomen will be acquired in healthy volunteers. 3D US-sim, 3D US-guide, 3D US-monitor and 4D US-monitor will be used to meet the following study objectives:
1. The accuracy of B-mode 3D US-guide, to estimate the position of the liver in breath-hold for verification of (1) daily set-up position (set-up US-guide) and (2) repeat breath hold relevant to radiotherapy delivery (BH 3D US-monitor), will be determined. Accuracy will be assessed by comparison of US-guide and US-monitor determined liver position with a manually determined 'gold standard' liver position.
2. Comparison of the accuracy of power Doppler and B-mode US-guide/US-monitor for the estimation of liver position during breath hold.
3. Assessment of the accuracy of 4D US-monitor to estimate liver motion during free breathing (FB).
4. Comparison of liver position stability using spirometry and voluntary breath-hold (vBH) using US-monitoring.
5. Assessment of the availability of a second or third ultrasound field of view for increasing the accuracy of US-guide based estimates of liver motion.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing.
Ultrasound imaging
Abdominal ultrasound imaging of the liver
Group B
Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing and in repeat spirometer assisted breath hold.
Ultrasound imaging
Abdominal ultrasound imaging of the liver
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ultrasound imaging
Abdominal ultrasound imaging of the liver
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Healthy volunteers who are unable to lie for extended period of time (up to 45 minutes including short breaks of a few minutes) on a hard surface (treatment couch).
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute of Cancer Research, United Kingdom
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emma J Harris, PhD
Role: PRINCIPAL_INVESTIGATOR
Institute of Cancer Research, United Kingdom
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCR4821
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.